Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from Analysts at Stifel Nicolaus

Stock analysts at Stifel Nicolaus initiated coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report issued on Friday, Briefing.com reports. The firm set a “buy” rating and a $49.00 price target on the stock. Stifel Nicolaus’ price target points to a potential upside of 88.46% from the company’s previous close.

A number of other research firms have also recently issued reports on ORKA. Leerink Partners assumed coverage on Oruka Therapeutics in a research report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price objective for the company. TD Cowen assumed coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set a “buy” rating for the company. Jefferies Financial Group assumed coverage on Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective for the company. Lifesci Capital assumed coverage on Oruka Therapeutics in a research report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price target for the company. Finally, HC Wainwright initiated coverage on Oruka Therapeutics in a research note on Monday. They set a “buy” rating and a $45.00 price target for the company. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Trading Down 8.6 %

Shares of ORKA stock opened at $26.00 on Friday. Oruka Therapeutics has a 1-year low of $18.72 and a 1-year high of $53.88. The firm has a market cap of $31.46 million, a PE ratio of -4.33 and a beta of 0.89.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($25.92) earnings per share (EPS) for the quarter. On average, equities research analysts anticipate that Oruka Therapeutics will post -1.62 EPS for the current year.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.